Personalized Medicine Potential of Cyclacel Pharmaceuticals, Inc.'s Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer Conference

Published: Nov 06, 2012

BERKELEY HEIGHTS, N.J., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today multiple posters presented on the Company's sapacitabine and on its Polo-Like Kinase 1 (Plk1) inhibitors during the 8th National Cancer Research Institute (NCRI) Cancer Conference being held November 4-7, 2012, Liverpool, United Kingdom.

Back to news